Murine models of acute leukemia: Important tools in current pediatric leukemia research

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Jacoby, Elad ^a   Chien, Christopher D ^a   Fry, Terry J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute lymphoblastic leukemia; Adoptive; Immunotherapy; Murine model; Syngeneic; Xenografts

Indexed keywords

8 [(4 AMINOBUTYL) (2 BENZIMIDAZOLYLMETHYL) AMINO] 1, 2, 3, 4 TETRAHYDROQUINOLINE; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; AFADIN PROTEIN; BCR ABL PROTEIN; CLATHRIN ASSEMBLY LYMPHOID MYELOID LEUKEMIA PROTEIN; CYTARABINE; DEXAMETHASONE; ELEVEN NINETEEN LEUKEMIA PROTEIN; ELL PROTEIN; ICG 001; LIM PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; NOTCH1 RECEPTOR; PANOBINOSTAT; PLERIXAFOR; PROTEIN; RAPAMYCIN; TEMSIROLIMUS; THYMIC STROMAL LYMPHOPOIETIN PROTEIN; TOPOTECAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR LYL1; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR TAL1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; AGGRESSIVENESS; ANIMAL MODEL; B LYMPHOCYTE; BONE MARROW; CANCER GENETICS; CANCER RESEARCH; CANCER STEM CELL; CELL THERAPY; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; FUSION GENE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MURINE LEUKEMIA; NONHUMAN; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84904706518     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00095     Document Type: Review

References (159)

1. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 9:1985-9.
2. Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol (2005) 15:162-74. doi: 10.1016/j.semcancer.2005.01.008
3. Dal Cin P, Atkins L, Ford C, Ariyanayagam S, Armstrong SA, George R, et al. Amplification of AML1 in childhood acute lymphoblastic leukemias. Genes Chromosomes Cancer (2001) 30:407-9. doi:10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C
4. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood (1996) 88:4252-8.
5. Fischer M, Schwieger M, Horn S, Niebuhr B, Ford A, Roscher S, et al. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. Oncogene (2005) 24:7579-91. doi:10.1038/sj.onc.1208931
6. Morrow M, Horton S, Kioussis D, Brady HJ, Williams O. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood (2004) 103:3890-6. doi:10.1182/blood-2003-10-3695
7. Tsuzuki S, Seto M, Greaves M, Enver T. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc Natl Acad Sci U S A (2004) 101:8443-8. doi:10.1073/pnas.0402063101
8. Bernardin F, Yang Y, Cleaves R, Zahurak M, Cheng L, Civin CI, et al. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res (2002) 62:3904-8.
9. Andreasson P, Schwaller J, Anastasiadou E, Aster J, Gilliland DG. The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet (2001) 130:93-104. doi:10.1016/S0165-4608(01)00518-0
10. Ford AM, Palmi C, Bueno C, Hong D, Cardus P, Knight D, et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest (2009) 119:826-36. doi:10.1172/JCI36428
11. Li M, Jones L, Gaillard C, Binnewies M, Ochoa R, Garcia E, et al. Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations. Leukemia (2013) 27:1570-3. doi:10.1038/leu.2013.15
12. Schindler JW, Van Buren D, Foudi A, Krejci O, Qin J, Orkin SH, et al. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell (2009) 5:43-53. doi:10.1016/j.stem.2009.04.019
13. van der Weyden L, Giotopoulos G, Rust AG, Matheson LS, van Delft FW, Kong J, et al. Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice. Blood (2011) 118:1041-51. doi:10.1182/blood-2011-02-338848
14. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet (1999) 354:1499-503. doi:10.1016/S0140-6736(99)09403-9
15. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood (1996) 87:1211-24.
16. Zhuang Y, Soriano P, Weintraub H. The helix-loop-helix gene E2A is required for B cell formation. Cell (1994) 79:875-84. doi:10.1016/0092-8674(94)90076-0
17. Sanyal M, Tung JW, Karsunky H, Zeng H, Selleri L, Weissman IL, et al. B-cell development fails in the absence of the Pbx1 proto-oncogene. Blood (2007) 109:4191-9. doi:10.1182/blood-2006-10-054213
18. Kamps MP, Wright DD, Lu Q. DNA-binding by oncoprotein E2a-Pbx1 is important for blocking differentiation but dispensable for fibroblast transformation. Oncogene (1996) 12:19-30.
19. Monica K, LeBrun DP, Dedera DA, Brown R, Cleary ML. Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable. Mol Cell Biol (1994) 14:8304-14.
20. Chang CP, de Vivo I, Cleary ML. The Hox cooperativity motif of the chimeric oncoprotein E2a-Pbx1 is necessary and sufficient for oncogenesis. Mol Cell Biol (1997) 17:81-8.
21. Kamps MP, Baltimore D. E2A-Pbx1, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice. Mol Cell Biol (1993) 13:351-7.
22. Dedera DA, Waller EK, LeBrun DP, Sen-Majumdar A, Stevens ME, Barsh GS, et al. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell (1993) 74:833-43. doi:10.1016/0092-8674(93)90463-Z
23. Bijl J, Sauvageau M, Thompson A, Sauvageau G. High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia. Genes Dev (2005) 19:224-33. doi:10.1101/gad.1268505
24. Feldman BJ, Reid TR, Cleary ML. Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice. Oncogene (1997) 15:2735-42. doi:10.1038/sj.onc.1201670
25. Feldman BJ, Hampton T, Cleary ML. A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood (2000) 96:1906-13.
26. Smith KS, Chanda SK, Lingbeek M, Ross DT, Botstein D, van Lohuizen M, et al. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol Cell (2003) 12:393-400. doi:10.1016/S1097-2765(03)00277-6
27. Seidel MG, Look AT. E2A-HLF usurps control of evolutionarily conserved survival pathways. Oncogene (2001) 20:5718-25. doi:10.1038/sj.onc.1204591
28. Gachon F, Fonjallaz P, Damiola F, Gos P, Kodama T, Zakany J, et al. The loss of circadian PAR bZip transcription factors results in epilepsy. Genes Dev (2004) 18:1397-412. doi:10.1101/gad.301404
29. Yoshihara T, Inaba T, Shapiro LH, Kato JY, Look AT. E2A-HLF-mediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF. Mol Cell Biol (1995) 15:3247-55.
30. Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H, et al. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). Blood (2010) 116:962-70. doi:10.1182/blood-2009-09-244673
31. Smith KS, Rhee JW, Naumovski L, Cleary ML. Disrupted differentiation and oncogenic transformation of lymphoid progenitors in E2A-HLF transgenic mice. Mol Cell Biol (1999) 19:4443-51.
32. Honda H, Inaba T, Suzuki T, Oda H, Ebihara Y, Tsuiji K, et al. Expression of E2A-HLF chimeric protein induced T-cell apoptosis, B-cell maturation arrest, and development of acute lymphoblastic leukemia. Blood (1999) 93:2780-90.
33. Smith KS, Rhee JW, Cleary ML. Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2. Mol Cell Biol (2002) 22:7678-87. doi:10.1128/MCB.22.21.7678-7688.2002
34. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood (2002) 99:1536-43. doi:10.1182/blood.V99.5.1536
35. Ribeiro RC, Abromowitch M, Raimondi SC, Murphy SB, Behm F, Williams DL. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood (1987) 70:948-53.
36. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature (1985) 315:758-61. doi:10.1038/315758a0
37. Voncken JW, van Schaick H, Kaartinen V, Deemer K, Coates T, Landing B, et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell (1995) 80:719-28. doi:10.1016/0092-8674(95)90350-X
38. Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell (1991) 65:1165-75. doi:10.1016/0092-8674(91)90012-N
39. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell (1991) 65:1153-63. doi:10.1016/0092-8674(91)90011-M
40. Harrison SC. Variation on an Src-like theme. Cell (2003) 112:737-40. doi:10.1016/S0092-8674(03)00196-X
41. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature (1990) 344:251-3. doi:10.1038/344251a0
42. Castellanos A, Pintado B, Weruaga E, Arevalo R, Lopez A, Orfao A, et al. A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. Blood (1997) 90:2168-74.
43. Foley SB, Hildenbrand ZL, Soyombo AA, Magee JA, Wu Y, Oravecz-Wilson KI, et al. Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia. Cell Rep (2013) 5:51-60. doi:10.1016/j.celrep.2013.08.037
44. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood (1995) 86:4603-11.
45. Honda H, Fujii T, Takatoku M, Mano H, Witte ON, Yazaki Y, et al. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood (1995) 85:2853-61.
46. Honda H, Oda H, Suzuki T, Takahashi T, Witte ON, Ozawa K, et al. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. Blood (1998) 91:2067-75.
47. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet (2000) 24:57-60. doi:10.1038/71691
48. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 247:824-30. doi:10.1126/science.2406902
49. Uchida N, Hanawa H, Dan K, Inokuchi K, Shimada T. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector. J Nippon Med Sch (2009) 76:134-47. doi:10.1272/jnms.76.134
50. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J (1990) 9:1069-78.
51. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A (1990) 87:6649-53. doi:10.1073/pnas.87.17.6649
52. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med (1999) 189:1399-412. doi:10.1084/jem.189.9.1399
53. Stripecke R, Skelton DC, Gruber T, Afar D, Pattengale PK, Witte ON, et al. Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor. Hum Gene Ther (1998) 9:2049-62. doi:10.1089/hum.1998.9.14-2049
54. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A (1993) 90:3755-9. doi:10.1073/pnas.90.8.3755
55. Pui CH, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC, et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol (1994) 12:909-15.
56. Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia (1995) 9:762-9.
57. Meyer C, Hofmann J, Burmeister T, Groger D, Park TS, Emerenciano M, et al. The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 27:2165-76. doi:10.1038/leu.2013.135
58. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. MLL partial tandem duplications in acute leukemia cell lines. Leukemia (2003) 17:980-1. doi:10.1038/sj.leu.2402911
59. Tamai H, Miyake K, Takatori M, Miyake N, Yamaguchi H, Dan K, et al. Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia (2011) 25:888-91. doi:10.1038/leu.2011.15
60. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood (2006) 108:669-77. doi:10.1182/blood-2005-08-3498
61. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN, et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene (2006) 25:3093-103. doi:10.1038/sj.onc.1209636
62. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 14:355-68. doi:10.1016/j.ccr.2008.10.001
63. Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell (2010) 17:148-59. doi:10.1016/j.ccr.2009.12.034
64. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, Dingermann T, et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood (2010) 115:3570-9. doi:10.1182/blood-2009-06-229542
65. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell (1996) 85:853-61. doi:10.1016/S0092-8674(00)81269-6
66. Collins EC, Pannell R, Simpson EM, Forster A, Rabbitts TH. Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Rep (2000) 1:127-32. doi:10.1093/embo-reports/kvd021
67. Xu SM, Yang Y, Zhou M, Zhao XJ, Qin Y, Zhang PL, et al. Establishment of the retrovirus-mediated murine model with MLL-AF9 leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2013) 21:1126-32. doi:10.7534/j.issn.1009-2137.2013.05.008
68. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 442:818-22. doi:10.1038/nature04980
69. Forster A, Pannell R, Drynan LF, McCormack M, Collins EC, Daser A, et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell (2003) 3:449-58. doi:10.1016/S1535-6108(03)00106-5
70. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J (1997) 16:4226-37. doi:10.1093/emboj/16.14.4226
71. Zeisig BB, Garcia-Cuellar MP, Winkler TH, Slany RK. The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene (2003) 22:1629-37. doi:10.1038/sj.onc.1206104
72. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U, et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol (2003) 24:617-28. doi:10.1128/MCB.24.2.617-628.2004
73. Horton SJ, Walf-Vorderwulbecke V, Chatters SJ, Sebire NJ, de Boer J, Williams O. Acute myeloid leukemia induced by MLL-ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities. Blood (2009) 113:4922-9. doi:10.1182/blood-2008-07-170480
74. DiMartino JF. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood (2002) 99:3780-5. doi:10.1182/blood.V99.10.3780
75. Fu JF, Hsu CL, Shih LY. MLL/AF10(OM-LZ)-immortalized cells expressed cytokines and induced host cell proliferation in a mouse bone marrow transplantation model. Int J Cancer (2010) 126:1621-9. doi:10.1002/ijc.24867
76. Fu JF, Yen TH, Chen Y, Huang YJ, Hsu CL, Liang DC, et al. Involvement of Gpr125 in the myeloid sarcoma formation induced by cooperating MLL/AF10(OM-LZ) and oncogenic KRAS in a mouse bone marrow transplantation model. Int J Cancer (2013) 133:1792-802. doi:10.1002/ijc.28195
77. DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, Cleary ML, et al. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood (2000) 96:3887-93.
78. Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood (2013) 121:2533-41. doi:10.1182/blood-2012-11-465120
79. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 446:758-64. doi:10.1038/nature05690
80. Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med (2011) 208:1135-49. doi:10.1084/jem.20101947
81. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 116:1165-76. doi:10.1002/cncr.24862
82. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1985) 318:533-8. doi:10.1038/318533a0
83. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med (1988) 167:353-71. doi:10.1084/jem.167.2.353
84. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, et al. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res (2005) 65:1306-15. doi:10.1158/0008-5472.CAN-04-0268
85. Yu D, Thomas-Tikhonenko A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene (2002) 21:1922-7. doi:10.1038/sj.onc.1205244
86. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol (2008) 3:587-613. doi:10.1146/annurev.pathmechdis.3.121806.154300
87. Weng AP, Ferrando AA, Lee W, Morris JPT, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306:269-71. doi:10.1126/science.1102160
88. Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE, et al. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood (2008) 112:3373-82. doi:10.1182/blood-2008-03-147587
89. Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA, et al. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation. J Biol Chem (2013) 288:18219-27. doi:10.1074/jbc.M113.475376
90. Chiang MY, Xu L, Shestova O, Histen G, L'Heureux S, Romany C, et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest (2008) 118:3181-94. doi:10.1172/JCI35090
91. D'Altri T, Gonzalez J, Aifantis I, Espinosa L, Bigas A. Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemia. Cell Cycle (2011) 10:1031-6. doi:10.4161/cc.10.7.15067
92. Beverly LJ, Capobianco AJ. Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in NotchIC-induced T cell leukemogenesis. Cancer Cell (2003) 3:551-64. doi:10.1016/S1535-6108(03)00137-5
93. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 8:83-93. doi:10.1038/nrc2290
94. Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, de Alboran IM, Nakayama K, et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med (2007) 204:2875-88. doi:10.1084/jem.20062299
95. Aplan PD, Jones CA, Chervinsky DS, Zhao X, Ellsworth M, Wu C, et al. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J (1997) 16:2408-19. doi:10.1093/emboj/16.9.2408
96. Aplan PD, Lombardi DP, Reaman GH, Sather HN, Hammond GD, Kirsch IR. Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood (1992) 79:1327-33.
97. Condorelli GL, Facchiano F, Valtieri M, Proietti E, Vitelli L, Lulli V, et al. T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res (1996) 56:5113-9.
98. O'Neil J, Billa M, Oikemus S, Kelliher M. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene (2001) 20:3897-905. doi:10.1038/sj.onc.1204519
99. Zhong Y, Jiang L, Hiai H, Toyokuni S, Yamada Y. Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice. Oncogene (2007) 26:6937-47. doi:10.1038/sj.onc.1210494
100. Neale GA, Rehg JE, Goorha RM. Ectopic expression of rhombotin-2 causes selective expansion of CD4-CD8- lymphocytes in the thymus and T-cell tumors in transgenic mice. Blood (1995) 86:3060-71.
101. Larson RC, Fisch P, Larson TA, Lavenir I, Langford T, King G, et al. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene (1994) 9:3675-81.
102. Draheim KM, Hermance N, Yang Y, Arous E, Calvo J, Kelliher MA. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice. Oncogene (2011) 30:1252-60. doi:10.1038/onc.2010.495
103. Caudell D, Zhang Z, Chung YJ, Aplan PD. Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. Cancer Res (2007) 67:8022-31. doi:10.1158/0008-5472.CAN-06-3749
104. Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, Pott C, et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell (2006) 10:363-74. doi:10.1016/j.ccr.2006.08.023
105. Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia (2013) 27:813-22. doi:10.1038/leu.2012.327
106. Watanabe S, Shimosato Y, Kameya T, Kuroki M, Kitahara T, Minato K, et al. Leukemic distribution of a human acute lymphocytic leukemia cell line (Ichikawa strain) in nude mice conditioned with whole-body irradiation. Cancer Res (1978) 38:3494-8.
107. Ziegler HW, Frizzera G, Bach FH. Successful transplantation of a human leukemia cell line into nude mice: conditions optimizing graft acceptance. J Natl Cancer Inst (1982) 68:15-8.
108. Hara H, Luo Y, Haruta Y, Seon BK. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6. Cancer Res (1988) 48:4673-80.
109. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature (1983) 301:527-30. doi:10.1038/301527a0
110. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol (2007) 7:118-30. doi:10.1038/nri2017
111. Kamel-Reid S, Letarte M, Doedens M, Greaves A, Murdoch B, Grunberger T, et al. Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. Blood (1991) 78:2973-81.
112. Kamel-Reid S, Letarte M, Sirard C, Doedens M, Grunberger T, Fulop G, et al. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science (1989) 246:1597-600. doi:10.1126/science.2595371
113. Uckun FM, Downing JR, Chelstrom LM, Gunther R, Ryan M, Simon J, et al. Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood (1994) 84:859-65.
114. Kawata A, Yoshida M, Okazaki M, Yokota S, Barcos M, Seon BK. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. Cancer Res (1994) 54:2688-94.
115. Mosier DE, Stell KL, Gulizia RJ, Torbett BE, Gilmore GL. Homozygous scid/scid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J Exp Med (1993) 177:191-4. doi:10.1084/jem.177.1.191
116. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 13:5426-35. doi:10.1158/1078-0432.CCR-07-0674
117. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol (1995) 154:180-91.
118. Borgmann A, Baldy C, von Stackelberg A, Beyermann B, Fichtner I, Nurnberg P, et al. Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol (2000) 17:635-50. doi:10.1080/08880010050211349
119. Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R, Falkenburg JH. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Exp Hematol (2001) 29:322-9. doi:10.1016/S0301-472X(00)00669-X
120. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood (2002) 99:4100-8. doi:10.1182/blood.V99.11.4100
121. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood (2007) 109:674-82. doi:10.1182/blood-2006-06-030445
122. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood (2004) 103:3905-14. doi:10.1182/blood-2003-08-2911
123. Diamanti P, Cox CV, Blair A. Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice. Leukemia (2012) 26:376-80. doi:10.1038/leu.2011.212
124. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G, et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer (2008) 123:2222-7. doi:10.1002/ijc.23772
125. Morisot S, Wayne AS, Bohana-Kashtan O, Kaplan IM, Gocke CD, Hildreth R, et al. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia (2010) 24:1859-66. doi:10.1038/leu.2010.184
126. Woiterski J, Ebinger M, Witte KE, Goecke B, Heininger V, Philippek M, et al. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcgammanull mice reflects individual leukemogenecity and highly correlates with clinical outcome. Int J Cancer (2013) 133:1547-56. doi:10.1002/ijc.28170
127. Lavender KJ, Pang WW, Messer RJ, Duley AK, Race B, Phillips K, et al. BLT-humanized C57BL/6 Rag2-/-gammac-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood (2013) 122:4013-20. doi:10.1182/blood-2013-06-506949
128. le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 14:47-58. doi:10.1016/j.ccr.2008.05.015
129. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science (2008) 319:336-9. doi:10.1126/science.1150648
130. Welschinger R, Liedtke F, Basnett J, Dela Pena A, Juarez JG, Bradstock KF, et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol (2013) 41: 293-302.e1. doi:10.1016/j.exphem.2012.11.004
131. Messinger Y, Chelstrom L, Gunther R, Uckun FM. Selective homing of human leukemic B-cell precursors to specific lymphohematopoietic microenvironments in SCID mice: a role for the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5. Leuk Lymphoma (1996) 23:61-9. doi:10.3109/10428199609054803
132. Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Blood (1995) 85:2537-45.
133. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood (2004) 104:2919-25. doi:10.1182/blood-2004-03-0901
134. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M, et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia (2008) 22:1207-13. doi:10.1038/leu.2008.83
135. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood (2009) 113:3287-96. doi:10.1182/blood-2008-04-154187
136. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci U S A (1998) 95:4584-8. doi:10.1073/pnas.95.8.4584
137. Cazzaniga G, van Delft FW, Lo Nigro L, Ford AM, Score J, Iacobucci I, et al. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood (2011) 118:5559-64. doi:10.1182/blood-2011-07-366542
138. Uckun FM, Sather H, Reaman G, Shuster J, Land V, Trigg M, et al. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood (1995) 85:873-8.
139. Uckun FM. Severe combined immunodeficient mouse models of human leukemia. Blood (1996) 88:1135-46.
140. Meyer LH, Eckhoff SM, Queudeville M, Kraus JM, Giordan M, Stursberg J, et al. Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. Cancer Cell (2011) 19:206-17. doi:10.1016/j.ccr.2010.11.014
141. Meyer LH, Debatin KM. Diversity of human leukemia xenograft mouse models: implications for disease biology. Cancer Res (2011) 71:7141-4. doi:10.1158/0008-5472.CAN-11-1732
142. Guihard S, Peyrouze P, Cheok MH. Pharmacogenomic considerations of xenograft mouse models of acute leukemia. Pharmacogenomics (2012) 13:1759-72. doi:10.2217/pgs.12.158
143. Uckun FM, Stewart CF, Reaman G, Chelstrom LM, Jin J, Chandan-Langlie M, et al. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood (1995) 85:2817-28.
144. Barrett DM, Seif AE, Carpenito C, Teachey DT, Fish JD, June CH, et al. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood (2011) 118:e112-7. doi:10.1182/blood-2011-04-346528
145. Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, Fish J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood (2008) 112:2020-3. doi:10.1182/blood-2008-02-137141
146. Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia (2011) 25:1314-23. doi:10.1038/leu.2011.76
147. Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia (2012) 26:1517-26. doi:10.1038/leu.2012.31
148. Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene (2014) 33, 2169-78. doi:10.1038/onc.2013.169
149. Canale S, Cocco C, Frasson C, Seganfreddo E, Di Carlo E, Ognio E, et al. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia (2011) 25:1815-24. doi:10.1038/leu.2011.158
150. Uckun FM, Qazi S, Cely I, Sahin K, Shahidzadeh A, Ozercan I, et al. Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood (2013) 121:4348-54. doi:10.1182/blood-2012-11-470633
151. Lu H, Kojima K, Battula VL, Korchin B, Shi Y, Chen Y, et al. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol (2014) 93:485-92. doi:10.1007/s00277-013-1939-2
152. Agnusdei V, Minuzzo S, Frasson C, Grassi A, Axelrod F, Satyal S, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia (2014) 28:278-88. doi:10.1038/leu.2013.183
153. Messinger Y, Yanishevski Y, Avramis VI, Ek O, Chelstrom LM, Gunther R, et al. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside. Clin Cancer Res (1996) 2:1533-42.
154. Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, et al. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leuk Lymphoma (2012) 53:1999-2003. doi:10.3109/10428194.2012.679267
155. Nijmeijer BA. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. Blood (2002) 100:654-60. doi:10.1182/blood.V100.2.654
156. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res (2006) 66:10995-1004. doi:10.1158/0008-5472.CAN-06-0160
157. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2013) 121:1165-74. doi:10.1182/blood-2012-06-438002
158. Ali N, Flutter B, Sanchez Rodriguez R, Sharif-Paghaleh E, Barber LD, Lombardi G, et al. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rgammanull mice display a T-effector memory phenotype. PLoS One (2012) 7:e44219. doi:10.1371/journal.pone.0044219
159. Kuwatsuka Y, Minami M, Minami Y, Sugimoto K, Hayakawa F, Miyata Y, et al. The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. Blood Cancer J (2011) 1:e17. doi:10.1038/bcj.2011.16